GCG and type 2 diabetes mellitus: Several approaches have been tried to elevate active GLP-1 of which DPP-IV inhibitors have proven to be the promising agents to treat type 2 diabetes mellitus (T2DM).[6] While the DPP-IV inhibitor, sitagliptin (Januvia®), was approved worldwide as a first-in-class drug, saxagliptin (ONGLYZA®) was recently approved by FDA and vildagliptin (Galvus®) by EU market.